Friday, October 3, 2014
CME-certified regional program in collaboration with Earle A. Chiles Research Institute, Providence Cancer Center
Bernard A. Fox, PhD – Earle A. Chiles Research Institute, Providence Cancer Center
Walter J. Urba, MD, PhD – Earle A. Chiles Research Institute, Providence Cancer Center
Asim Amin, MD, PhD – Levine Cancer Institute Carolinas Medical Center
Joseph W. Fay, MD – Baylor University Medical Center
Keith L. Knutson, PhD – Vaccine & Gene Therapy Institute of Florida
John D. Powderly II, MD, CPI – Carolina BioOncology Institute, PLLC
Brian I. Rini, MD – Cleveland Clinic Taussig Cancer Center
Alexander Spira, MD, PhD – Virginia Cancer Specialists
Specifically designed for clinical oncologists and the entire medical team involved in treating cancer patients with immunotherapy, this introductory, CME-certified program provided an understanding of basic immunology principles in the clinical application and management of cancer immunotherapy and discussed emerging drugs and concepts in the cancer immunotherapy field.
Presented by leading authorities in tumor immunology and cancer immunotherapy, this program facilitated understanding of 1) the underlying principles of tumor immunology and immunotherapy, 2) the clinical indications for cancer immunotherapy and appropriate selection of patients, 3) patient management, and 4) the therapeutic effectiveness of immunotherapy to ultimately improve patient outcomes.
Attendees also had the opportunity for professional networking that promotes collaboration and scientific exchange with experts, clinical oncologists and other health care providers from the surrounding community.
The target audience for this program included clinical oncologists, those involved in patient care, early career individuals, allied health professionals, and patient advocates who wish to learn principles of tumor immunology and immunotherapy, as well as improve their ability to select patients for immunotherapy and provide state-of-the-art clinical management for their patients.
Upon completion of this program, the participants should have been able to:
Jointly provided by Clinical Immunology Society (CIS) and Society for Immunotherapy of Cancer (SITC)
In collaboration with Earle A. Chiles Research Institute, Providence Cancer Center
The Advances of Cancer ImmunotherapyTM series is supported in part by educational grants from:
To view all of SITC’s supporters, please, click here.